Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Innovotech Inc V.IOT

Innovotech Inc. is a Canadian biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.


TSXV:IOT - Post by User

Bullboard Posts
Post by overnouton Aug 12, 2020 9:23am
90 Views
Post# 31397002

Q2 Earnings Out

Q2 Earnings Out

Edmonton - TheNewswire - August 11th, 2020 - Innovotech Inc. (TSXV:IOT) recorded revenue of $333,904 and net profit of $121,974 in its second quarter ended June 30th, 2020. The Q2 results benefited from $37,533 provided by the Canada Emergency Wage Subsidy program and from actions taken by stakeholders to reduce professional fees, rents, and interest expense. Contract research revenues of $291,881 were supported by generally lower than average MBEC Assay plate sales of $42,023, as device customers such as university laboratories adjusted their operations.

The stronger second quarter revenue and profit resulted in six-month revenues of $460,291, compared with $508,635 in the same period of 2019, and resulted in a year to date profit of $6,676 versus a loss of $19,549 in the first half of 2019

"We were able to overcome the worst effects of the COVID-19 Pandemic on our clients and customers that resulted in a weak first quarter" said Dr. Amin Omar, Chief Operating Officer. "We are looking forward to Q3 as we complete work started late in Q2 and continue to see growing requests for our services."

While technically an event subsequent to Q2, the July 14thannouncement of a Collaboration Agreement with a global medical device company regarding our InnovoSIL(TM)-1 compound was an important step forward for Innovotech. We are optimistic regarding potential commercial applications for this silver periodate anti-microbial.

 
Bullboard Posts